Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Transplantation. 2015 Jan 15;99(1):21–28. doi: 10.1097/TP.0000000000000545

Table I.

Summary of the functional and phenotypic heterogeneity evident of mouse memory B cells. Because memory B cells are quiescent, their characteristics are juxtaposed with those of naïve B cells. The PD-L2 and CD80 nomenclature is a new addition to the memory B cell cannon and not all parameters have been determined yet.

naïve Heterogeneity in B cell memory
Memory B cells Switched or Unswitched Memory B Cells
IgM IgM+ IgG+ IgA+ LLPC PD-L2loCD80lo PD-L2hiCD80hi
developmental route n.d. pre- & post-GC pre- & post-GC post-GC post-GC not known not known
tissue tropism recirculating recirculating recirculating Mucosal bone marrow and mucosal not known not known
S0HM none low or high low or high high low or high low high
life span brief indefinite decays not known indefinite indefinite indefinite
propensity for effector cell fates germinal center ≫ plasma cell limited by presence of high affinity antibody plasma cell ≫ germinal center plasma cell ≫ germinal center Inert germinal center ≫ plasma cell plasma cell ≫ germinal center
repertoire broad/low affinity archival? broad/low affinity unknown narrow/high affinity broad/low affinity not known
CD19 expression high high high high low/absent high high
CD20 expression high high high high low/absent high high
BAFFR expression high high high high high high high
BCMA expression low/absent low/absent low/absent low/absent high low/absent low/absent
Potential therapeutics Alemtuzumab
Rituximab
Belimumab
Atacicept
Rituximab
Belimumab
Atacicept
Rituximab
Belimumab
Atacicept
Rituximab
Bortezomib
Atacicept
IVIG
Plasmaphoresis
Belimumab
Atacicept
Rituximab
Belimumab
Atacicept
Rituximab